Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980556 | 0.90 | ALDH1A1 (0.61) | ALDH1A1CYP3A4TSHRTDP1KMT2A | |
| SCHEMBL3974772 | 0.84 | GCGR (0.53) | ALDH1A1ABCB1 | |
| SCHEMBL3978634 | 0.80 | CYP3A4 (0.56) | ALDH1A1CYP3A4KMT2A | |
| SCHEMBL3974631 | 0.78 | CTSA (0.47) | ALDH1A1CYP3A4KMT2A | |
| SCHEMBL3974199 | 0.76 | ALDH1A1 (0.59) | ALDH1A1CYP3A4KMT2A | |
| SCHEMBL3976996 | 0.76 | L3MBTL1 (0.51) | ALDH1A1CYP3A4KMT2A | |
| SCHEMBL3978024 | 0.76 | CYP3A4 (0.45) | ALDH1A1CYP3A4KMT2A | |
| SCHEMBL3977741 | 0.74 | GCGR (0.49) | ALDH1A1CYP3A4KMT2A | |
| SCHEMBL3979538 | 0.73 | ALDH1A1 (0.49) | ALDH1A1CYP3A4TSHRKMT2A | |
| SCHEMBL3978777 | 0.73 | CYP3A4 (0.43) | ALDH1A1CYP3A4KMT2AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | ALDH1A1 1389/4885CYP3A4 517/4885TSHR 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.